We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Stool Test for Detecting Colorectal Cancer Could Reduce Unnecessary Colonoscopies

By LabMedica International staff writers
Posted on 13 Feb 2024
Print article
Image: The new test can improve population-based colorectal cancer screening (Photo courtesy of Paul Maguire/Shutterstock.com)
Image: The new test can improve population-based colorectal cancer screening (Photo courtesy of Paul Maguire/Shutterstock.com)

Globally, around 1.9 million people are diagnosed with colorectal cancer each year, resulting in approximately 935,000 deaths. Early detection is key, as colorectal cancer can be cured if found early. However, symptoms like weight loss or blood in the stool often emerge too late for effective intervention. Consequently, many countries have initiated population-based screening programs. These programs commonly utilize the fecal immunochemical test (FIT), which detects the blood protein hemoglobin in stool samples. Colorectal cancer screening programs have been effective in diagnosing the disease at earlier stages and reducing mortality rates. Despite the current test’s effectiveness, there is a need for improvement, particularly in detecting larger premalignant polyps before they become invasive. Early detection would allow for these polyps to be removed during a colonoscopy instead of requiring surgery.

Researchers at the Netherlands Cancer Institute (Amsterdam, the Netherlandsl) have been developing a new test, the multitargetFIT-test (mtFIT), which measures hemoglobin and two additional proteins. An earlier retrospective study showed promising results. Now, a much larger, prospective study that compared the mtFIT to the current FIT in over 13,000 participants of the Dutch national population-based screening program has found that the new test yielded more positive results than the current test. This increase in positive results led to more colonoscopies being performed.

With the new mtFIT test, doctors found abnormalities in 299 individuals, compared to 159 individuals with the current FIT test. Most notably, the mtFIT identified a higher number of individuals with high-risk precursors to colon cancer (216 versus 114). The potential number of colorectal cancer cases that could be prevented using this new test varies, depending on how the current FIT test is implemented in different countries. For participants, the new test is as user-friendly as the existing one. Integrating mtFIT into existing FIT-based screening programs should be easy, as both tests require similar screening logistics.

“The new test can detect cancer precursors more effectively,” said Gerrit Meijer, Principal Investigator at the Netherlands Cancer Institute. “Our results predict that the test can reduce the number of new cases of colorectal cancer and mortality resulting from it. The new test detects more larger polyps without a significant increase in 'false-positive' results and thus unnecessary colonoscopies.”

Related Links:
Netherlands Cancer Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.